A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

Completed · Phase 3 · Has a placebo group

Conditions studied: Overweight, Obesity

In brief

The main purpose of this study is to evaluate the efficacy and safety of tirzepatide for the maintenance of body weight reduction.

Key facts

Study ID

NCT06047548

Run by

Eli Lilly and Company

People needed

441

Starts

2023-09-20

Expected to finish

2026-01-20

Last updated by the study team

2026-03-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Have a Body Mass Index (BMI) of ≥30 kilogram/square meter (kg/m²) or ≥27 kg/m² and previously diagnosed with at least 1 of the following weight related comorbidities:
• Hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease
• Have a history of at least 1 self-reported unsuccessful dietary effort to lose body weight (BW)

You may not qualify if…

• Have Type 1 Diabetes (T1D) or Type 2 Diabetes (T2D), a history of ketoacidosis, or hyperosmolar state or coma.
• Have a self-reported change in BW>5 kilogram (kg) within 3 months prior to screening
• Have a prior or planned surgical treatment for obesity, excluding liposuction or abdominoplasty if performed >1 year prior to screening.
• Have a history of chronic or acute pancreatitis
• Have any of the following cardiovascular conditions within 3 months prior to week 0.
• Acute myocardial infarction, cerebrovascular accident (stroke), unstable angina, and hospitalization due to congestive heart failure (CHF)
• family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)
• History of significant active or unstable major depressive disorder (MDD) or other severe psychiatric disorder within the last 2 years
• Any lifetime history of a suicide attempt

Where it is running

• Cahaba Research - Pelham — Pelham, Alabama, United States
• Velocity Clinical Research, Westlake — Los Angeles, California, United States
• Southern California Dermatology, Inc. — Santa Ana, California, United States
• Encompass Clinical Research — Spring Valley, California, United States
• New Horizon Research Center — Miami, Florida, United States
• Oviedo Medical Research — Oviedo, Florida, United States
• Rophe Adult and Pediatric Medicine/SKYCRNG — Union City, Georgia, United States
• East-West Medical Research Institute — Honolulu, Hawaii, United States
• Rocky Mountain Clinical Research — Idaho Falls, Idaho, United States
• Asha Clinical Research - Munster — Hammond, Indiana, United States
• Iowa Diabetes and Endocrinology Research Center — West Des Moines, Iowa, United States
• L-MARC Research Center — Louisville, Kentucky, United States
• Prime Health and Wellness/SKYCRNG — Fayette, Mississippi, United States
• Alliance for Multispecialty Research, LLC — Norman, Oklahoma, United States
• WR-Clinsearch, LLC — Chattanooga, Tennessee, United States
• The University of Texas Health Science Center at Houston — Bellaire, Texas, United States
• Velocity Clinical Research, Dallas — Dallas, Texas, United States
• Southern Endocrinology Associates — Mesquite, Texas, United States
• Pinnacle Clinical Research — San Antonio, Texas, United States
• Consano Clinical Research, LLC — Shavano Park, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.